I-Shenzhen JYMed Technology Co., Ltd. (ngemuva kwalokhu ebizwa ngokuthi i-JYMed) yasungulwa ngo-2009, igxile ocwaningweni, ekuthuthukisweni, ekukhiqizeni nasekuthengisweni kwama-peptide nemikhiqizo ehlobene ne-peptide. Ngesikhungo esisodwa socwaningo kanye nezisekelo zokukhiqiza ezintathu ezinkulu, i-JYMed ingomunye wabakhiqizi abakhulu bama-API e-peptide ahlanganiswe ngamakhemikhali e-China. Ithimba eliyinhloko lenkampani le-R&D liziqhayisa iminyaka engaphezu kwengu-20 yesipiliyoni embonini ye-peptide futhi seliphumelele ukuhlolwa kwe-FDA kabili. Uhlelo lwe-JYMed lwezimboni ze-peptide olubanzi futhi olusebenzayo lunikeza amakhasimende uhla olugcwele lwezinsizakalo, okuhlanganisa ukuthuthukiswa nokukhiqizwa kwama-peptide okwelapha, ama-peptide ezilwane, ama-antimicrobial peptides, nama-cosmetic peptides, kanye nokubhaliswa nokusekelwa kokulawula.

Imisebenzi Yebhizinisi Eyinhloko

1.Ukubhaliswa kwasekhaya nokwamazwe ngamazwe kwe-peptide APIs

2.Amapeptide ezilwane nezimonyo

3.Ama-peptide angokwezifiso kanye nezinsizakalo ze-CRO, CMO, OEM

Izidakamizwa ze-4.PDC (i-peptide-radionuclide, i-molecule ye-peptide-encane, i-peptide-protein, i-peptide-RNA)

Ngokungeziwe ku-Tirzepatide, i-JYMed ithumele imibhalo yokubhalisa ne-FDA kanye ne-CDE kweminye imikhiqizo embalwa ye-API, okuhlanganisa nezidakamizwa ezidumile njengamanje zekilasi le-GLP-1RA njenge-Semaglutide ne-Liraglutide. Amakhasimende azayo asebenzisa imikhiqizo ye-JYMed azokwazi ukubhekisela ngokuqondile inombolo yokubhalisa ye-CDE noma inombolo yefayela le-DMF lapho ethumela izicelo zokubhalisa ku-FDA noma ku-CDE. Lokhu kuzonciphisa kakhulu isikhathi esidingekayo sokulungiselela imibhalo yesicelo, kanye nesikhathi sokuhlola kanye nezindleko zokubuyekezwa komkhiqizo.